Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SHR4640 Combined With Febuxostat in Primary Gout and Hyperuricemia
NCT07362355Phase 2Recruiting
- Sponsor
- Hengrui
- Start
- Feb 2026
- Primary completion
- Jul 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of ruzinurad in primary gout, hyperuricemia, sponsored by Hengrui. Started Feb 2026; status: recruiting.
02
Drugs
ruzinurad
03
Conditions
primary gouthyperuricemia
Beyond the preview
Go deeper on NCT07362355.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07362355.